Apnimed, Inc. (APMD) · Sep 8, 2026 · Earnings

Apnimed posts $126M profit on one-offs as Oxnimbi launch prep accelerates

In line — No reliable consensus; $11.7M operating loss versus $125.9M net income driven by one-time gains

Apnimed’s headline profit is largely transaction-driven, while FDA review and $221M of IPO proceeds move Oxnimbi toward commercialization.

There is no clean consensus benchmark to call this quarter a beat or miss. Published estimates appear sparse and inconsistent for a newly listed company, so the meaningful read is operational rather than the headline EPS comparison.

The quarter’s reported profit is mostly accounting-driven, not a sign of a profitable operating model. Apnimed generated a $11.7 million operating loss, while $142.5 million of gains from selling its equity-method investment and reversing a deposit liability produced $125.9 million of net income (Statements of Operations). The company itself says, “Net income was $125.9million for the quarter ended June 30, 2026, compared to a net loss of $69.5million for the quarter ended June 30, 2025.”

MetricQ2 2026ComparisonRead
Revenue related party$12.1M$17.1M in Q2 2025Lower (Statements of Operations)
Research and development expense$9.9M$16.0M in Q2 2025Lower as Phase 3 trials ended (Financial Results)
General and administrative expense$12.7M$5.4M in Q2 2025More than doubled for launch preparation (Financial Results)
Operating income (loss)$(11.7)M$(5.9)M in Q2 2025Wider operating loss (Statements of Operations)
Net income (loss)$125.9M$(69.5)M in Q2 2025Distorted by one-time gains (Statements of Operations)
Cash and equivalents$172.8M$41.9M at December 31, 2025Before subsequent IPO proceeds (Balance Sheets)

The real change is balance-sheet capacity and commercial spending, not earnings power. The company subsequently raised $220.8 million gross in its IPO and secured access to a credit facility of up to $150 million, while G&A rose to $12.7 million as it built pricing, market-access, forecasting and product-positioning capabilities. The filing says, “Completed its upsized initial public offering for gross proceeds of $220.8million.”

The key product milestone is now a regulatory decision, but much of the headline news was already known. The FDA accepted the Oxnimbi NDA and set a February 28, 2027 PDUFA date, while the IPO, leadership appointments and Shionogi-Apnimed monetization were already completed before this filing. The filing states, “The FDA has assigned a Prescription Drug User Fee Act (“PDUFA”) target action date of February 28, 2027.” 〔0〕

Net read: operationally in line, strategically better funded, but financially mixed. The company has moved from trial execution toward launch preparation and has materially strengthened its cash position, but the quarter does not demonstrate recurring revenue or operating profitability. The next decisive benchmark is the FDA’s February 28, 2027 action date.

What to watch next

FDA PDUFA decision for Oxnimbi, February 28, 2027

Original filing on SEC EDGAR

Apnimed posts $126M profit on one-offs as Oxnimbi launch prep accelerates | APMD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.